$RVMD

Revolution Medicines will present clinical data on its RAS(ON) inhibitor pipeline at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich, Germany, from July 1–4, 2026. The company intends to showcase four presentations covering Phase 1/2 and Phase 3 trials for targeted therapies addressing RAS-addicted cancers, including pancreatic ductal adenocarcinoma (PDAC).

How Zoldonrasib Targets RAS-Addicted Cancers

Revolution Medicines is focusing on zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, as a potential treatment for metastatic PDAC. According to the company’s June 24, 2026, announcement, researchers will report findings from two specific combination regimens. The first evaluates zoldonrasib paired with chemotherapy in a first-line setting. The second report tracks the drug’s performance when combined with daraxonrasib in patients who have already undergone one or more prior lines of therapy.

What the RASolute Clinical Trials Aim to Achieve

The ESMO congress will also feature two “trials-in-progress” posters for the company’s RASolute Phase 3 program. The RASolute 303 study compares daraxonrasib—a RAS(ON) multi-selective inhibitor—against the current standard of care for first-line metastatic PDAC treatment. The trial design measures the efficacy of daraxonrasib both as a monotherapy and in combination with gemcitabine and nab-paclitaxel.

Additionally, the RASolute 304 study is evaluating the use of adjuvant daraxonrasib. This trial targets patients who have already undergone surgical resection and completed perioperative chemotherapy. By moving into the adjuvant space, Revolution Medicines aims to determine if these targeted therapies can prevent recurrence in patients following initial surgical intervention.

Comparing Targeted RAS(ON) Therapies

Revolution Medicines is distinguishing its approach by focusing on “RAS(ON)” inhibitors, which are designed to bind directly to the active state of RAS proteins. The following table highlights the current clinical focus for their primary candidates:

Frequently Asked Questions

What is the primary goal of the upcoming ESMO presentations?

The presentations will provide updated clinical data on the safety, tolerability, and efficacy of zoldonrasib and daraxonrasib in treating various forms of RAS-addicted gastrointestinal cancers.

Are these treatments currently approved for general use?

No. According to the company’s SEC filings, these candidates are currently in clinical development and are subject to ongoing trials and regulatory approval processes.

What makes RAS(ON) inhibitors different from previous therapies?

Unlike traditional approaches that may struggle to bind to mutated RAS, these inhibitors are designed to specifically suppress the active, oncogenic forms of RAS proteins, which are frequent drivers in pancreatic and other cancers.